To date, the biomarkers most commonly used to predict the efficacy of ICBs include expression level of programmed cell death‐ligand 1 (PD‐L1) [8], tumor mutational burden (TMB) [9], microsatellite instability (MSI) [10], and circulating tumor DNA (ctDNA) [7]. This evidence concerns the gene CD274 and neoplasm.